During the third quarter of 2025, Havas recorded a strong organic performance. It posted net revenue1 of 656 million euros, up +3.8% organically compared to the same period of 2024, which benefited from a favorable level of comparison (organic growth of -2.3% in third-quarter 2024). This satisfactory performance is attributable to underlying business development in each division during the third quarter of 2025, notably in the Healthcare division.
Changes in the scope of consolidation2 had a positive 1.0% impact on net revenue, while changes in foreign exchange rates3 had a negative 3.9% impact. This impact is notably due to the decrease in the US dollar and Latin American currencies compared to the same period last year (for detailed figures, please see the appendix to this press release).
Revenue for third quarter 2025 totaled 681 million euros, up 1.1% as reported compared to the third quarter of 2024 (up 3.9% on an organic basis).
For the first nine months of 2025, Havas recorded organic growth of +2.8%. This satisfactory performance is notably sustained by robust growth recorded with the Group’s top 30 clients, in accordance with the strategy of boosting service cross-fertilization with existing clients (In-Business).